Fractals: Life Science Conversations

Data analytics expert, systems and operations specialist, optimization and automation wizard—that’s our Senior Partner, Ben Mitchell. Previously the founder of tech startup The Brite Mind, then Vice President of Operations and Information Services and Analytics here at Bracken, Ben now works in a consulting capacity. Join Ben and host Colin Miller on this episode of Fractals: Life Science Conversations to discuss innovation across life science technology and data analytics, including:

• The evolution of digital advertising and growth marketing towards empowering clients through technology,
• The pivotal role of data as a cornerstone in life sciences and the importance of an integrated approach in both human interaction and platform creation,
• The construction of analytics and data structures for problem-solving, and how tailored data analytics in life sciences can unlock vast potential and opportunities, and,
• The essential guideposts for successful data analytics projects, including feasibility, team dynamics, stakeholder buy-in, and robust project planning.

A professional problem solver—that’s our Senior Partner, Marybeth Profrock. With a wealth of experience in accelerating growth for life sciences and digital health companies, Marybeth thrives on crafting innovative marketing solutions. Throughout her career, she’s specialized in digital innovation, B2B marketing, and content strategy, driving tangible results through analytical problem solving and meticulous execution. Tune in to the latest episode of Fractals to hear Marybeth and host Colin Miller turn the essential questions of life sciences marketing on their head, including:

• The importance of a comprehensive assessment and understanding of client requirements in crafting effective marketing or business strategies.
• Why analyzing the elements of effective marketing begins with addressing any problems at the root and how often foundational components quickly become critical to overall success.
• What the future potential of generative AI is within marketing strategies, a future contingent upon asking the right questions, and
• Why the backbone of any client project is continuous communication (and why it’s critical for any successful one). 

Head of Regulatory Affairs, FDA communications expert, and Managing Partner: That’s Liz Bloss. Join us for this episode of Fractals: Life Science Conversations as we welcome Liz to the program. Liz brings a wealth of experience, from formulating early IND submission strategies to guiding companies through the complexities of NDA preparations. With a sharp focus on FDA communications and meeting readiness, Liz adeptly navigates milestone gatherings crucial for development program success. Her proficiency extends to maneuvering orphan drug submissions, providing US Agent support, and delivering invaluable regulatory feedback. Tune in to get the inside scoop on all thing regulatory from Liz, including:

• The significance of attentive listening and strategic pauses in achieving regulatory goals and fostering meaningful connections.
• Establishing communication channels between scientific and regulatory spheres to forge pathways with FDA or regulatory bodies.
• Understanding how regulatory affairs transcends paperwork and emphasizes the need for innovative interpretation and thinking outside traditional confines.
• Recognizing the importance of cultivating personal relationships, networking opportunities, and empowering women in the life sciences industry to foster an inclusive environment that embraces diverse perspectives.

Groundbreaking science and entrepreneurial spirit go hand-in-hand with our latest guest: osteoarthritis expert and Senior Partner, Jon Larkin. With over two decades of research in pharma and biotech giants as well as his own startup, Jon shares insights on pioneering osteoarthritis therapies, leading clinical development efforts, and shaping the world of biopharma in academics, industry, and consortia alike. In this episode of Fractals, join Jon and host Colin Miller for valuable insights on:

• How the dynamic evolution of osteoarthritis drug development has permeated the industry, and its impact on treatment strategies. 
• The symbiotic relationship between leadership, collaboration, and success in healthcare.
• The intricacies of navigating critical decision points and regulatory challenges to advance clinical studies effectively, and...
• Unveiling the origins of drugs, from academia to industry, and the pivotal role of consortia in innovation.

Former Chief Medical Officer, Vice President of Nuclear Medicine, and long-time academic physician—that's our in-house nuclear medicine expert, Dr. Sandy McEwan. From research and publications in the academic space to hands-on development of novel SRTs, Sandy’s expertise is as developed as it is broad. Join Sandy and host Colin Miller on this episode of Fractals to hear key insights on: 

• The evolving landscape of nuclear medicine, radioisotope therapy, and radiopharmaceuticals in light of technological advancements, and a glimpse into their future. 
• Defining success metrics in nuclear medicine and how they are influenced by treatment modalities.
• The collaborative potential between industry and academia in advancing groundbreaking treatments and introducing new options for patients.
• The importance of prioritizing patient-centered approaches in the advancement of radiopharmaceutical therapies. 

At the forefront of digital healthcare technology, patient-centric initiatives, financial oversight, and integrated due diligence—that’s our accomplished Senior Partner, Martin Collyer. From orchestrating financial balance to crafting comprehensive due diligence strategies and addressing the pivotal need for personalized patient engagement in modern healthcare, Martin has consistently excelled at driving success with real results.

Join Martin and host Colin Miller in this episode of Fractals: Life Science Conversations to glean crucial insights on:

• The imperative of patient-centric initiatives in the ever-evolving digital healthcare landscape,
• The comprehensive view of opportunities and risks behind successful healthcare due diligence,
• The metrics and benchmarks defining effectiveness in the front-facing side of life sciences, and
• The significance of treating each patient’s journey and experience on a personalized scale for positive and succinct results.

Tune in to Fractals: Life Science Conversations on your preferred podcast platform for this and other valuable episodes.

Dr. Deepak Behera is no stranger to the puzzles of radiopharmaceutical development and life sciences marketing. That’s why, on this episode of Fractals: The Life Sciences Questionnaire, he shared his perspectives on holistic clinical development strategies and the importance of breaking siloed communication, as well as: 

• Why pairing the needs of patients with clinical development strategy is essential for driving positive health outcomes
• Diversifying accessibility to clinical trials through community physician and hospital participation
• Integrated approaches to marketing and business strategy, and risk mitigation
• Breaking barriers in clinical development, and the importance of soft skills

Brad Wyman’s seen a few things over his 30-year career: the potential of medical imaging, the limits of biomarker development, and the struggles and successes inherent to translational medicine. Join host Colin Miller as Brad shares stories from the front lines of clinical development. 

• Why successful biomarkers don’t guarantee clinical success
• Engineers vs. scientists, and how Brad distinguishes between them 
• Integrated approaches to marketing and business strategy
• The impact of AI, and where Brad would invest a hypothetical $100M (hint: it’s not AI)

With 50+ M&A deals to her name, Dawn Flitcraft knows what it takes to bring successful deals home, and spot problematic projects early on. Join host Colin Miller as Dawn serves as our Aristotle through the ethical landscape of M&A, with valuable takeaways at every turn:

• 4 key components of successful (and unsuccessful!) deals
• Principles for effective post-deal marketing
• Steering executive teams through M&A
• When emotion becomes an “X” factor
• Operation Warp Speed and Dawn’s time leading ethical review at WCG IRB